Amgen Inc.

Oliver Thiel

Michael J Martinelli

Robert D Larsen

James Richard Falsey

Neeraj Jagdish Agrawal

Sheng Cui

Kevin Graham

Liang Huang

Bradley J Herberich

Jason S Tedrow

Charles Bernard

Christopher Mohr

Robert Ronald Milburn

Austin G Smith

Dante Romanini

Philipp C Roosen

Alan H Cherney

Matthew G Beaver

John T Colyer

Kyle D Baucom

Gabrielle St-pierre

Masooma Tamim Raza

Rahul P Sangodkar

Michael A Lovette

Ari Ericson

Alex W Jacobitz

Ray Lieh Yoon Low

Victoria Wagner

Stephen Smith

John K Kawooya

Michael John Martinelli

Michal Achmatowicz

Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound F that can be used to prepare them where the variable PG is as defined herein. In particular, provided herein are processes for synthesizing compound A1, and salts or solvates thereof and compound A2, and salts and solvates thereof.

Ring closing synthesis of macrocyclic MCL-1 inhibitor intermediates

The present invention is directed to a CH3-containing molecule comprising (a) a first polypeptide comprising a CH3 domain and a negatively charged domain comprising consecutive negatively charged amino acid residues; and (b) a second polypeptide comprising a CH3 domain and a positively charged domain comprising consecutive positively charged amino acid residues. Also provided are methods for conjugating synthetic molecules to a multi-specific antigen binding molecule.

Bispecific antibodies with cleavable C-terminal charge-paired tags

Methods of preparing cinacalcet, cinacalcet derivatives, and salts thereof is disclosed herein. Also disclosed herein are polymorphs of cinacalcet, compositions of cinacalcet, and methods of treating a subject by administering cinacalcet, wherein cinacalcet is prepared by the disclosed methods.

Methods of synthesizing cinacalcet and salts thereof

Growing community of inventors

Camarillo, CA, United States of America

Oliver Thiel